MiMedx Group, Inc (MDXG) Given Average Rating of “Hold” by Brokerages
MiMedx Group, Inc (NASDAQ:MDXG) has received a consensus rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $12.40.
A number of equities analysts have recently commented on the stock. First Analysis cut shares of MiMedx Group from an “equal weight” rating to an “underweight” rating and set a $11.00 target price on the stock. in a report on Tuesday, May 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price (up from $12.00) on shares of MiMedx Group in a report on Thursday, April 13th. Finally, BidaskClub raised shares of MiMedx Group from a “hold” rating to a “buy” rating in a report on Saturday, June 24th.
Shares of MiMedx Group (MDXG) traded up 0.26% on Monday, reaching $15.49. 959,922 shares of the company’s stock were exchanged. MiMedx Group has a one year low of $6.94 and a one year high of $16.20. The firm has a 50 day moving average of $14.65 and a 200 day moving average of $10.68. The firm has a market capitalization of $1.64 billion, a P/E ratio of 110.64 and a beta of 1.04.
MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Friday, April 28th. The medical equipment provider reported $0.07 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.07. MiMedx Group had a net margin of 5.72% and a return on equity of 12.25%. The company had revenue of $72.60 million for the quarter, compared to analysts’ expectations of $72.60 million. During the same quarter last year, the company earned $0.04 earnings per share. The firm’s revenue for the quarter was up 36.1% on a year-over-year basis. On average, equities research analysts predict that MiMedx Group will post $0.30 EPS for the current year.
In other news, insider William Charles Taylor sold 26,000 shares of MiMedx Group stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $11.40, for a total value of $296,400.00. Following the transaction, the insider now directly owns 540,460 shares of the company’s stock, valued at approximately $6,161,244. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold a total of 132,571 shares of company stock worth $1,823,086 over the last ninety days. Corporate insiders own 12.40% of the company’s stock.
A number of institutional investors have recently bought and sold shares of the stock. Comerica Bank raised its position in MiMedx Group by 5.5% in the fourth quarter. Comerica Bank now owns 107,442 shares of the medical equipment provider’s stock worth $942,000 after buying an additional 5,568 shares during the period. UBS Asset Management Americas Inc. raised its position in MiMedx Group by 56.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 74,013 shares of the medical equipment provider’s stock worth $656,000 after buying an additional 26,713 shares during the period. Teachers Advisors LLC raised its position in MiMedx Group by 1.7% in the fourth quarter. Teachers Advisors LLC now owns 209,027 shares of the medical equipment provider’s stock worth $1,852,000 after buying an additional 3,438 shares during the period. Wells Fargo & Company MN raised its position in MiMedx Group by 9.5% in the first quarter. Wells Fargo & Company MN now owns 471,131 shares of the medical equipment provider’s stock worth $4,491,000 after buying an additional 41,028 shares during the period. Finally, Tudor Investment Corp Et Al purchased a new position in MiMedx Group during the fourth quarter worth $159,000. Hedge funds and other institutional investors own 55.76% of the company’s stock.
About MiMedx Group
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Receive News & Ratings for MiMedx Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group Inc and related companies with MarketBeat.com's FREE daily email newsletter.